Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Herpes Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
NCT07633197Phase 1Enrolling by invitation
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- May 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in herpes zoster (HZ) (3 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoints: Adverse Events/Reactions at 30 days and Incidence of adverse events/reactions after administration at 30 days. Started May 2026; status: enrolling by invitation.
02
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07633197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07633197.